Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

Video content above is prompted by the following: 

IMMagine-1 Phase 2 Study of Anitocabtagene Autoleucel in R/R MM


The iMMagine-1 trial evaluates anitocabtagene autoleucel (anti-BCMA chimeric antigen receptor [CAR] T-cell therapy) in patients with R/R MM. Preliminary results focus on efficacy and safety in heavily pretreated patients, including those refractory to triple-class (proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies) and penta-class therapies.

High response rates were observed, even in penta-refractory patients, suggesting durable disease control in a population with limited treatment options.

Depth of response correlated with improved progression-free survival, reinforcing the potential of BCMA-targeted CAR T therapy in later-line settings.

Toxicities were consistent with prior CAR T therapies, including cytokine release syndrome and neurotoxicity, but were generally manageable.

Further follow-up is needed to assess long-term safety and durability of responses.

The efficacy in triple- and penta-refractory patients may shift treatment paradigms, positioning BCMA-targeted CAR T therapy earlier in the disease course.

Potential integration into sequencing strategies for R/R MM, especially in those failing standard regimens

These results reinforce the role of CAR T therapies in overcoming resistance mechanisms in heavily pretreated myeloma.

The durability of response may challenge the reliance on continuous therapy models, offering the possibility of fixed-duration treatment with sustained benefit.

Optimization of patient selection and bridging strategies

Comparative studies with bispecific antibodies and other emerging BCMA-directed therapies

These findings highlight anitocabtagene autoleucel as a promising therapeutic option in the evolving R/R MM landscape, warranting continued investigation in larger cohorts.

Videos

Panelists discuss how the preliminary results from the iMMagine-1 trial of anitocabtagene autoleucel in relapsed/refractory multiple myeloma (R/R MM) highlight promising efficacy in triple-class and penta-class refractory patients, potentially reshaping treatment strategies and challenging existing paradigms in managing heavily pretreated myeloma.

Application of Real-World Evidence in Selecting CAR T in R/R MM

Chimeric Antigen Receptor (CAR) T-Cell Therapy in R/R MM

Panelists discuss how real-world comparative analyses reveal nuanced differences in the efficacy and safety profiles of ciltacabtagene autoleucel and idecabtagene vicleucel among patients with R/R MM, highlighting the critical importance of translating clinical trial data into practical treatment strategies.

The retrospective intention-to-treat analysis by Amoozgar et al presented at ASH 2024 (abstract #2408) offers several important perspectives:

: Real-world studies demonstrate that CAR T-cell therapy outcomes can differ significantly from controlled clinical trial settings due to patient heterogeneity, comorbidities, and prior treatment histories.

: The study likely compared the efficacy and safety of 2 different CAR T-cell therapies (ciltacabtagene autoleucel and idecabtagene vicleucel) in actual clinical practice.

: Real-world data help refine patient selection criteria and predict more personalized treatment responses beyond initial clinical trial parameters.

: The analysis would have shed light on potential adverse events, treatment-related complications, and long-term tolerability in a more diverse patient population.

Panelists discuss how real-world comparative analyses reveal nuanced differences in the efficacy and safety profiles of ciltacabtagene autoleucel and idecabtagene vicleucel among patients with relapsed/refractory multiple myeloma (R/R MM), highlighting the critical importance of translating clinical trial data into practical treatment strategies.

Panelists discuss how real-world analyses of chimeric antigen receptor (CAR) T-cell therapies in relapsed/refractory multiple myeloma (R/R MM), as presented in abstract #2408 by Amoozgar et al at ASH 2024, provide insights into the comparative efficacy and safety of ciltacabtagene autoleucel and idecabtagene vicleucel, highlighting differences between real-world outcomes and clinical trial results.

Insights From the Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

CAR T-Cell Therapies in R/R Multiple Myeloma: Real-World Insights

This retrospective intention-to-treat analysis compared the real-world efficacy and safety of 2 CAR T-cell therapies: ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) in R/R MM.

Evaluated real-world outcomes to bridge the gap between controlled clinical trials and actual patient experiences

Aimed to understand how these therapies perform in a more diverse, less controlled patient population

Comparative effectiveness of 2 different CAR T-cell approaches

Practical considerations for treatment selection

Patient outcomes outside of strict clinical trial protocols

Helps physicians make more informed treatment decisions

Offers a more nuanced understanding of CAR T-cell therapy performance in R/R MM

Panelists discuss how key data from ASH 2024 impact current approaches to treating hematologic malignancies, with a focus on multiple myeloma, lymphoma, and leukemia.

Welcome to This OncLive Peer Exchange: Highlighting Key Abstracts From ASH 2024

ASH 2024 Oncology Highlights for Physicians: Multiple Myeloma CAR T-Cell Therapy

 Peer Exchange focused on key data presented at the American Society of Hematology (ASH) 2024 Annual Meeting. The panel features experts:

The discussion aims to highlight significant abstracts and foster expert dialogue on recent developments in hematologic malignancies, specifically focusing on lymphoma, leukemia, and multiple myeloma.

The first abstract (#2408) under discussion examines real-world data comparing ciltacabtagene autoleucel (cilta-cel) vs idecabtagene vicleucel (ide-cel) in patients with relapsed multiple myeloma. Dr Parmar is invited to provide insights on how this real-world evidence might inform clinical decision-making for patients with multiple myeloma and potentially influence treatment selection between these 2 chimeric antigen receptor (CAR) T-cell therapies.

The discussion emphasizes the value of real-world data in understanding how approved therapies perform in clinical practice outside the controlled environment of clinical trials.

Harsh Parmar, MD

Articles

Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

Application of Real-World Evidence in Selecting CAR T in R/R MM

Insights From the Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

Welcome to This OncLive Peer Exchange: Highlighting Key Abstracts From ASH 2024